Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Induction Treatment With Nab-paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and Nab-paclitaxel/Gemcitabine or Continuing Application of Nab-paclitaxel/Gemcitabine: A Randomized Phase II Study

NCT02564146 is registered in ClinicalTrials.gov with AIO-Studien-gGmbH as lead sponsor.

NCT NCT02564146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02564146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Induction Treatment With Nab-paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and Nab-paclitaxel/Gemcitabine or Continuing Application of Nab-paclitaxel/Gemcitabine: A Randomized Phase II Study
Lead sponsor
AIO-Studien-gGmbH
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2016
Completion date
May 31, 2022
Enrollment
325 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, metastatic pancreatic cancer